P-Cymene

P-Cymene

SCHEMBL4860410

Cc1ccc(C(C)C)cc1.[Ru]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.50
TDP1 Q9NUW8 1/20 0.50
CHRNA7 P36544 1/20 0.48
TYR P14679 2/20 0.46
BCHE P06276 1/20 0.46
LMNA P02545 1/20 0.44
PTGS1 P23219 2/20 0.42
HTT P42858 1/20 0.42
TRPA1 O75762 1/20 0.42
CACNA1C Q13936 1/20 0.42
IDO1 P14902 2/20 0.41
CNR2 P34972 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN2A Q99250 1/20 0.41
ALOX5 P09917 1/20 0.40
MGLL Q99685 1/20 0.39
PTGS2 P35354 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Cymene SCHEMBL3684076 1.00 ACHE (0.50) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL29006180 1.00 ACHE (0.50) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL30626114 0.97 ACHE (0.47) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL6274941 0.97 ACHE (0.47) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL6510505 0.97 ACHE (0.47) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL2570692 0.97 ACHE (0.47) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL4005540 0.97 ACHE (0.47) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL1143 0.97 ACHE (0.53) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL1697748 0.97 ACHE (0.53) ACHETDP1CHRNA7TYRBCHE
P-Cymene SCHEMBL1897619 0.94 ACHE (0.44) ACHETDP1CHRNA7TYRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119505185-A PAF supported ruthenium catalyst and preparation method and application thereof 南昌大学 2025-02-25 CN claimed
CN-119191978-A Method for synthesizing meta-secondary alkyl substituted aryl carboxylic acid 华南理工大学 2024-12-27 CN claimed
CN-119101254-A COF composite material and preparation method and application thereof 南昌大学 2024-12-10 CN claimed
CN-118684579-A Method for preparing 2-methyl-4-acetoxyl-2-butenal by one-step method 浙江芳原馨生物医药有限公司 2024-09-24 CN claimed
CN-117924171-A Phenanthrone derivative and synthesis method thereof 华南理工大学 2024-04-26 CN claimed
CN-117902990-A Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol 海化生命(厦门)科技有限公司 2024-04-19 CN claimed
CN-117886819-A Synthesis method of L-5-methyltetrahydrofolate and calcium salt thereof 无锡紫杉药业股份有限公司 2024-04-16 CN claimed
CN-117820380-A Ruthenium complex with light responsiveness and preparation method and application thereof 广西医科大学 2024-04-05 CN claimed
CN-117776958-A Aromatic hydrocarbon carboxylic acid meta-position alkylation product and synthesis method thereof 华南理工大学 2024-03-29 CN claimed
CN-117736224-A Synthetic method of spiropyran compound 河南农业大学 2024-03-22 CN claimed
CN-109195937-A Acetic acid and hydrogen are generated in water-bearing media by ethyl alcohol and acetaldehyde by organic/inorganic catalyst 沙特基础工业全球技术公司 2019-01-11 CN claimed
US-10053480-B1 Anti-quorum and DNA cleaving agent KING SAUD UNIVERSITY (SA) 2018-08-21 US claimed
EP-2906569-B1 HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES USING PEROXIDE PROMOTERS MOMENTIVE PERFORMANCE MAT INC (US) 2018-06-13 EP claimed
CN-105294449-B Preparation method for (R)-(+)-1-(1-naphthyl)ethylamine and (S)-(-)-1-(1-naphthyl)ethylamine 连云港手性化学有限公司 2017-02-08 CN claimed
CN-105294449-A Preparation method for (R)-(+)-1-(1-naphthyl)ethylamine and (S)-(-)-1-(1-naphthyl)ethylamine LIANYUNGANG CHIRAL CHEMICAL CHINA CO LTD 2016-02-03 CN claimed
CN-105189419-A Metathesis process comprising the extraction of the ethylene formed by means of a membrane ARKEMA FRANCE 2015-12-23 CN claimed
CN-103003231-A Novel method for preparing phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor ACTAVIS GROUP PTC EHF 2013-03-27 CN claimed
CN-102264672-A Process for preparing optically active compounds using transfer hydrogenation 2011-11-30 CN claimed
WO-2002040494-A1 RUTHENIUM-ARYL-COMPOUNDS IN CANCER THERAPY UNIVERSITY OF YORK (GB) 2002-05-23 WO claimed
CN-1349971-A Olfination method of itaconic acid and succinic acid derivatives PFIZER (US) 2002-05-22 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053480-B1 Anti-quorum and DNA cleaving agent API5, RNGTT, XRCC6 ACHE 938/4885TDP1 34/4885CHRNA7 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.